(redirected from Copegus)
Also found in: Dictionary, Medical.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for ribavirin

an inhaled antiviral agent (trade name Virazole) that may be used to treat serious virus infections

References in periodicals archive ?
The study aims to further improve treatment outcomes by examining whether genotype 2 and 3 patients who do not have a rapid virological response at 4 weeks should have treatment with Pegasys and Copegus extended to 48 weeks.
Copegus can increase the toxicity of certain drugs used to treat HIV.
The programme is said to be tailored for those patients taking Janssen's hep C pill Incivo (telaprevir) with Roche's injectable interferon treatments Pegasys and Copegus.
The partnership will also initially focus on seven medications dispensed through CVS Caremark's specialty pharmacy business: Pegasys and Copegus for treatment of hepatitis C; as well as oncology drugs Glsevec, Tasigna, SpryceI, Tarceva and Tykerb.
Albuterol * Airet, Proventil, Ventolin, Volmax Ipratropium * Apo-Ipravent, Atrovent, Kendral-Ipratropium Racemic epinephrine * micoNephrine,Vaponefrin Ribavirin * Copegus, Rebetol, Virazole
The safety profile was typical for Pegasys and Copegus in populations with abnormal ALT levels, Dr.
Recommended Dosage: 180 [micro]g of Pegasys administered subcutaneously once a week, and (depending on HCV genotype) 800-1,200 mg of Copegus by mouth daily, for 24 or 48 weeks.
Hoffmann-La Roche for its own version of ribavirin, Copegus, globally.
The first study is designed to provide clinical data on the use of VICTRELIS (boceprevir), an oral HCV NS3/4A protease inhibitor, in combination with mericitabine (RO5024048), Roche's investigational oral HCV NS5B nucleoside polymerase inhibitor, Pegasys (pegylated interferon alfa-2a) and Copegus (ribavirin), in adult patients with chronic HCV genotype 1 infection who had a null response to prior peginterferon alfa and ribavirin therapy (less than a 2 log HCV-RNA decline at treatment week 12).
In addition, the partnership will initially focus on seven medications dispensed through CVS Caremark's specialty pharmacy business, including Pegasys and Copegus, for the treatment of hepatitis C, as well as the oncology drugs Gleevec, Tasigna, Sprycel, Tarceva and Tykerb.
Copegus has not been directly compared with Schering-Plough's combination of Peg-Intron (pegintefferon alfa-2b) and Rebetol, approved in 2001 to treat HCV in interferon-a-naive adults with compensated liver disease.
ILLUMINATE was an open-label, randomised Phase III study that evaluated INCIVEK in combination with Pegasys (pegylated-interferon alfa-2a) and Copegus (ribavirin) in 540 people with genotype 1 chronic hepatitis C.
Ribavirin Tablets, 500 Zydus Pharmaceuticals Copegus Tablets